カテゴリ： GlobalData, アメリカ, 企業調査

Apricus Biosciences Inc (APRI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Apricus Biosciences Inc (APRI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10050
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Apricus Biosciences Inc (Apricus) develops and commercializes pharmaceutical products indicated for the treatment of various therapeutic classes including urology and rheumatology. Its product pipeline includes, Vitaros (alprostadil), a topical vasodilator cream in-licensed from Warner Chilcott Inc for the treatment of erectile dysfunction; and RayVa or alprostadil topical cream, product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. The company develops these products using its proprietary permeation enhancement technology, namely, NexACT, designed to enhance delivery of an active drug to the patient. It operates along with its subsidiaries in British Virgin Islands, and the US. Apricus is headquartered in San Diego, California, the US.

Apricus Biosciences Inc (APRI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Apricus Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Apricus Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 14
Apricus Biosciences Completes Acquisition Of NitroMist Rights From NovaDel Pharma For US$0.2 Million 15
Venture Financing 16
Apricus Biosciences Raises USD10 Million in Venture Financing 16
Partnerships 17
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 17
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 18
Merger 19
Apricus Biosciences to Merge with Seelos Therapeutics 19
Licensing Agreements 21
Apricus Biosciences Enters into Licensing Agreement with Allergan 21
Apricus Expands Licensing Agreement with Hexal for Vitaros 22
Apricus Biosciences Enters into Licensing Agreement with Forendo Pharma for Fispemifene 23
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 25
Apricus Biosciences Enters Into Licensing Agreement With Laboratoires Majorelle For Vitaros 26
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 27
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For MycoVa 28
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 29
Apricus Biosciences Enters Into Licensing Agreement With Stellar Pharma For MycoVa 30
Apricus Biosciences Expands Licensing Agreement With Hexal For Vitaros 31
Equity Offering 32
Apricus Biosciences Raises USD3.55 Milllion in Public Offering of Shares 32
Apricus Biosciences to Raise USD3.7 Million in Private Placement of Shares and Warrants 33
Apricus Biosciences Files Registration Statement for Public Offering of Shares for USD6.9 Million 34
Apricus Biosciences Raises USD3.7 Million in Registered Direct Offering 35
Apricus Biosciences to Raise up to USD7 Million in Private Placement of Shares 36
Apricus Biosciences Raises USD7.8 Million in Second and Final Tranche of Private Placement of Shares and Warrants 38
Apricus Biosciences Raises USD2.2 Million in First Tranche of Private Placement of Shares and Warrants 40
Apricus Biosciences Raises USD11 Million in Private Placement of Shares and Warrants 42
Apricus Biosciences Completes First Tranche of Private Placement of Shares for USD2 Million 43
Apricus Biosciences Completes Public Offering Of Shares For US$17 Million 44
Apricus Biosciences Announces Private Placement Of Shares For US$17.2 Million 46
Apricus Biosciences Completes Public Offering Of Units For US$20 Million 47
Asset Transactions 49
Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 49
Biocodex Acquires Rights To Totect, Anthracycline Extravasation Medicine, From Apricus Biosciences 51
Mist Pharma Acquires Rights To NitroMist From Apricus Biosciences 52
Acquisition 53
Apricus Biosciences Completes Acquisition Of Finesco For Up To US$11 Million 53
Apricus Biosciences Inc – Key Competitors 54
Apricus Biosciences Inc – Key Employees 55
Apricus Biosciences Inc – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Oct 31, 2018: Apricus Biosciences provides corporate update and third quarter 2018 financial results 57
Aug 09, 2018: Apricus Biosciences provides corporate update and second quarter 2018 financial results 58
May 03, 2018: Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results 59
Mar 01, 2018: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results 60
Nov 02, 2017: Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results 61
Aug 02, 2017: Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results 62
May 11, 2017: Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results 63
Mar 13, 2017: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Apricus Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Apricus Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Apricus Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 14
Apricus Biosciences Completes Acquisition Of NitroMist Rights From NovaDel Pharma For US$0.2 Million 15
Apricus Biosciences Raises USD10 Million in Venture Financing 16
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 17
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 18
Apricus Biosciences to Merge with Seelos Therapeutics 19
Apricus Biosciences Enters into Licensing Agreement with Allergan 21
Apricus Expands Licensing Agreement with Hexal for Vitaros 22
Apricus Biosciences Enters into Licensing Agreement with Forendo Pharma for Fispemifene 23
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 25
Apricus Biosciences Enters Into Licensing Agreement With Laboratoires Majorelle For Vitaros 26
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 27
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For MycoVa 28
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 29
Apricus Biosciences Enters Into Licensing Agreement With Stellar Pharma For MycoVa 30
Apricus Biosciences Expands Licensing Agreement With Hexal For Vitaros 31
Apricus Biosciences Raises USD3.55 Milllion in Public Offering of Shares 32
Apricus Biosciences to Raise USD3.7 Million in Private Placement of Shares and Warrants 33
Apricus Biosciences Files Registration Statement for Public Offering of Shares for USD6.9 Million 34
Apricus Biosciences Raises USD3.7 Million in Registered Direct Offering 35
Apricus Biosciences to Raise up to USD7 Million in Private Placement of Shares 36
Apricus Biosciences Raises USD7.8 Million in Second and Final Tranche of Private Placement of Shares and Warrants 38
Apricus Biosciences Raises USD2.2 Million in First Tranche of Private Placement of Shares and Warrants 40
Apricus Biosciences Raises USD11 Million in Private Placement of Shares and Warrants 42
Apricus Biosciences Completes First Tranche of Private Placement of Shares for USD2 Million 43
Apricus Biosciences Completes Public Offering Of Shares For US$17 Million 44
Apricus Biosciences Announces Private Placement Of Shares For US$17.2 Million 46
Apricus Biosciences Completes Public Offering Of Units For US$20 Million 47
Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 49
Biocodex Acquires Rights To Totect, Anthracycline Extravasation Medicine, From Apricus Biosciences 51
Mist Pharma Acquires Rights To NitroMist From Apricus Biosciences 52
Apricus Biosciences Completes Acquisition Of Finesco For Up To US$11 Million 53
Apricus Biosciences Inc, Key Competitors 54
Apricus Biosciences Inc, Key Employees 55
Apricus Biosciences Inc, Subsidiaries 56

List of Figures
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Apricus Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Apricus Biosciences Inc (APRI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • STATS ChipPAC Pte Ltd：企業の戦略的SWOT分析
    STATS ChipPAC Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Compumedics Ltd (CMP)：企業の財務・戦略的SWOT分析
    Summary Compumedics Ltd (Compumedics) is a medical device company that develops and commercializes computer-based medical products. The company designs, develops and commercializes computer aided medical diagnostic systems. It provides product categories such as sleep diagnostics, neurology diagnost …
  • Advicenne SA (ADVIC)：製薬・医療：M&Aディール及び事業提携情報
    Summary Advicenne SA (Advicenne) is a developer of pediatric medicines. The company offers product portfolio such as ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic premedication; ADV7103, a formulation in the form of micro-tablets for renal tubulopathies. It p …
  • CGI Group Inc.：企業の戦略・SWOT・財務情報
    CGI Group Inc. - Strategy, SWOT and Corporate Finance Report Summary CGI Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • SSM Health Care：企業の戦略的SWOT分析
    SSM Health Care - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Gildan Activewear Inc (GIL)：企業の財務・戦略的SWOT分析
    Gildan Activewear Inc (GIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bangkok Bank Public Co Ltd：企業の戦略・SWOT・財務情報
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • SunTrust Banks Inc：企業の戦略・SWOT・財務情報
    SunTrust Banks Inc - Strategy, SWOT and Corporate Finance Report Summary SunTrust Banks Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Electro Optic Systems Holdings Ltd (EOS)：企業の財務・戦略的SWOT分析
    Electro Optic Systems Holdings Ltd (EOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Samsung Electro-Mechanics Co Ltd (009150)：企業の財務・戦略的SWOT分析
    Samsung Electro-Mechanics Co Ltd (009150) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Shopping Centres Australasia Property Group RE Limited：企業の戦略・SWOT・財務情報
    Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report Summary Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Erste Group Bank AG：企業の戦略・SWOT・財務情報
    Erste Group Bank AG - Strategy, SWOT and Corporate Finance Report Summary Erste Group Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Nippon Soda Co., Ltd.：企業の戦略・SWOT・財務情報
    Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Ferro Corp (FOE)：企業の財務・戦略的SWOT分析
    Ferro Corp (FOE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Tav Havalimanlari Holding AS：戦略・SWOT・企業財務分析
    Tav Havalimanlari Holding AS - Strategy, SWOT and Corporate Finance Report Summary Tav Havalimanlari Holding AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Direct Conversion AB：企業の戦略的SWOT分析
    Direct Conversion AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Synthetic Biologics Inc (SYN)：企業の財務・戦略的SWOT分析
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • Carl Zeiss Meditec AG (AFX)：医療機器：M&Aディール及び事業提携情報
    Summary Carl Zeiss Meditec AG (Carl Zeiss Meditec), a division of Carl Zeiss AG, is an integrated medical technology company, which provides visualization solutions for minimally invasive surgical treatments. It operates in the fields of ophthalmology, neuro/ENT surgery and surgical ophthalmology. T …
  • MYnd Analytics Inc (MYND)：製薬・医療：M&Aディール及び事業提携情報
    Summary MYnd Analytics Inc (MYnd Analytics), formerly CNS Response Inc, is a predictive analytics company. The company develops a decision support tool that assists physicians in the provision of personalized medication for individual patients suffering from mental health issues. It provides Psychia …
  • Moberg Pharma AB (MOB)-医療機器分野：企業M&A・提携分析
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB is a pharmaceutical company that offers medical products for the treatment of skin diseases. The company offers products which include Emtrix, Nalox and Naloc, Kerasal nail, Kerasal foot ointment, Domeboro, Blamex and Balmex adult ca …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆